News

In an interview with Targeted Oncology, Haris Ali, MD, a hematology oncologist at the City of Hope Cancer Center, discussed the efficacy of ruxolitinib in patients with myelofibrosis, the impact of mutations on ruxolitinib treatment, and the use of the agent in the peri-transplant setting.

The FDA’s Oncologic Drugs Advisory Committee met to discuss the need, validity, and reliability of using patient-reported outcomes measurements linked to the Common Terminology Criteria for Adverse Events in pediatric oncology.

Melissa, K. Frey, MD, the study of adequate collection of family cancer history in ovarian and other gynecological cancers in order to determine cancer risk and early interventions.

Sumanta Kumar Pal, MD, a medical oncologist at the City of Hope Cancer Center, discussed the SWOG 1500 trial, the potential of cabozantinib for the treatment of papillary RCC, and the future of RCC care in an interview with Targeted Oncology,

Two newly-approved CAR T-cell agents are now being used to treat patients with relapsed/refractory non-Hodgkin lymphoma and multiple myeloma at University Hospitals in Ohio.

The FDA has granted orphan drug designation to the first-in-class ruthenium-based small molecule, BOLD-100, for the treatment of patients with gastric cancer.

In an interview with Targeted Oncology, Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses HER2-positive metastatic breast cancer innovations, treatments, and upcoming studies.

Distinct gene signatures and BRCAness may correlate with pathologic complete response and invasive disease-free survival in patients with HER2-positive breast cancer treated with trastuzumab and pertuzumab with or without paclitaxel.

Treatment with neratinib demonstrated a modest overall survival benefit in patients with HER2-positive breast cancer compared with placebo, according to the long-term OS and central nervous system results from the phase 3 ExteNET trial.

According to findings from a subgroup analysis of the TALAPRO-1 trial, men with heavily pretreated metastatic castration-resistant prostate cancer, with germline and/or homozygous tumor DNA damage response alterations are most likely to respond to talazoparib.

In an interview with Targeted Oncology, William H. Bradley, MD, discussed the results of the SOLO-1 trial of olaparib as a maintenance therapy for patients with ovarian cancer with a BRCA1/2 mutation, and other developments in the ovarian cancer field.

The combination of durvalumab, tremelimumab, and chemotherapy showed statistically significant and clinically meaningful overall survival benefit compared to chemotherapy alone for the first-line treatment of patients with metastatic non-small cell lung cancer.

In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.

Vivek Subbiah, MD, discusses the updated results of the LIBRETTO-001 trial, specifically the effect of selpercatinib on RET fusion-positive thyroid tumors.

In a study of 300 phase 3 clinical trials, researchers have found that the gap of enrollment age and the median age of patients diagnosed with cancer is increasing.

Avelumab was explored in a clinical trial for the treatment of locally advanced head and neck squamous cell carcinoma, but more research is needed to position the agent and other checkpoint inhibitors in the treatment landscape, experts say.

In an interview with Targeted Oncology, Vivek Subbiah, MD, reviewed the data supporting selpercatinib as treatment of RET fusion-positive thyroid cancers, as well as the exploration of this agent in other RET-altered cancers.

The FDA has granted priority review to 2 supplemental new drug applications for the combination use of pembrolizumab and lenvatinib.

In patients with multiple myeloma, the combination of motixafortide and granulocyte colony-stimulating factor achieved a 4.9-fold increase in hematopoietic stem-cell mobilization, and prepared most patients for autologous stem cell transplant, meeting both the primary and main secondary endpoints of the GENESIS Study.

With the treatment landscape rapidly developing with the approval of new agents and the investigation of various combination regimens, understanding the individual profiles of each agent will aid treatment selection.

Patients with mantle cell lymphoma treated with second-line ibrutinib or the R-BAC regimen experienced improvement in progression-free survival 2 compared with treatment on rituximab and bendamustine and other regimens, according to findings from the international, retrospective MANTLE-FIRST study.

Targeted Oncology is proud to partner with the American Society of Clinical Pathology to present a 1-hour webinar with an expert panel, moderated by Dan Milner, MD, MSc, MBA.

The FDA accepted a supplemental new drug application for ivosidenib tablets and granted it priority review for the treatment of patients with previously treated IDH1-mutated cholangiocarcinoma.

Findings from the PROfound and National Comprehensive Cancer Network guidelines for molecular testing were reviewed for a discussion on treatment for 60-year-old man with metastatic castration-resistant prostate cancer.

In lung cancer, the historic absence of clear biomarkers to identify patients who could derive benefit from MET-specific therapy has kept the field from moving forward with potential therapies.

Regardless of HER2 status, patients with human leukocyte antigen-A02, node-positive and high-risk node-negative breast cancer, had significant improvement in responses with a GP2 peptide vaccine plus GM-CSF compared with GM-CSF alone.

In an interview with Targeted Oncology, Mato, a hematologic oncologists and the director of the CLL Program at Memorial Sloan Kettering Cancer Center, discussed biomarker testing in CLL, and the future of BTK inhibitors in the CLL paradigm. 

Xiuning Le, MD, PhD, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer.

The relapse-free survival benefit observed with rituximab maintenance added to autologous stem cell transplant suggests that the treatment strategy may help with disease eradication.

Masitinib in combination with docetaxel helps to prolong progression-free survival in metastatic castrate-resistant prostate cancer eligible to chemotherapy compared to placebo in combination with docetaxel, meeting the primary end point of the phase 3 AB12003 study.